



ANNUAL MEETING PROGRAMME

Thursday 30 September 2021

09.30-10.00	POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>
10.00-10.10	Opening of the Annual HAI Meeting – Prof. James O'Donnell, President
	SESSION 1 – Oral Presentations 6 x 10 minute Presentations Chairpersons: Prof. James O'Donnell and Dr Su Maung
10.10-10.20	CHD4 LOSS IN ACUTE MYELOID LEUKAEMIA GIVES RISE TO INCREASED DNA DAMAGE REPAIR DEFECTS AND ALTERED CELL CYCLE PROGRESSION Deirdre Venney, QUB
10.20-10.30	RECREATING THE BONE MARROW MICROENVIRONMENT TO MODEL LEUKEMIC STEM CELL QUIESCENCE Eimear O'Reilly, NUIG
10.30-10.40	COVID-19 CONVALESCENT PLASMA, THE NORTHERN IRELAND BTS EXPERIENCE Andrea Piccin, NIBTS
10.40-10.50	VENETOCLAX AND EPIGENETIC MODIFIERS: PROMISING NOVEL COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA Lyndsay Flanagan, RCSI
10.50-11.00	CHIMERIC ANTIGEN RECEPTOR T-CELL (CART) THERAPY IN IRISH CHILDREN WITH RELAPSED/REFRACTORY PAEDIATRIC B-ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) Valerie Broderick, CHI at Crumlin
11.00-11.10	NOVEL INSIGHTS INTO THE ROLE OF VON WILLEBRAND FACTOR IN THE PATHOGENESIS OF PAEDIATRIC SICKLE CELL DISEASE Helen Fogarty, RCSI
11.10-11.20	NATURAL HISTORY OF VACCINE-INDUCED THROMBOCYTOPENIA AND THROMBOSIS (VITT) IN IRELAND Dawn Swan, St James's Hospital, Dublin
11.20-11.30	INVESTIGATION OF SAMPLES REFERRED FOR IMMUNE HAEMOLYTIC ANAEMIA: TWO CASES REFERRED TO THE NATIONAL BLOOD CENTRE Eileen Ryan, IBTS
11.30-11.40	DETERMINING EFFECTIVE DRUG COMBINATIONS FOR PAEDIATRIC ACUTE MYELOID LEUKAEMIA Áine McGill, Patrick G Johnston Centre for Cancer Research, CCRCB
11.40-11.50	IMPACT OF P53 DISRUPTION ON MANTLE CELL LYMPHOMA (MCL) TREATMENT OUTCOME Rehman Faryal, UHW & GUH
11.50-12.00	USE OF CALCULATED GLOBULIN FOR DEMAND TARGETING OF MULTIPLE MYELOMA TESTING Aisling O'Brien, Cork University Hospital
12.00-12.45	STATE OF THE ART LECTURE: Introduced by: Dr Barry Kevane <i>Advances in the treatment of patient with Sickle Cell Disease: Are we approaching a new era?</i> Professor Jo Howard, Consultant Haematologist Guy's and St Thomas' NHS Foundation Trust, London, Honorary Professor King's College
12.45-13.30	POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>



ANNUAL MEETING PROGRAMME

Thursday 30 September 2021

13.30	Session 2: Chairpersons: Dr Siobhan Glavey & Prof. Feargal McNicholl
13.30-14.15	STATE OF THE ART LECTURE: Introduced by: Dr Siobhan Glavey <i>Coagulopathy & COVID-19: Clinical Challenges and Therapeutic Opportunities</i> <i>Dr Barry Kevane, Consultant Haematologist</i> <i>Mater Misericordiae University Hospital</i>
14.15 -14.25	CD49D EXPRESSION IN CLL IS STRONGLY ASSOCIATED WITH NOTCH1 MUTATIONS AND REDUCED TIME TO FIRST-TREATMENT Aidan Kelly, Trinity St. James' Cancer Institute
14.25-14.35	EZH2 LOSS DYSREGULATES CELLULAR METABOLISM AND SENSITIZES AML CELLS TO BCL2 INHIBITION Dr Luke Jones, Systems Biology Ireland, UCD
14.35-14.45	THE BURDEN OF ANAEMIA AND EXTENT OF SCREENING FOR IRON, B12, AND FOLATE DEFICIENCY AMONG PATIENTS IN THE IRISH HEALTH SYSTEM: A COHORT STUDY Conor Clancy, University of Limerick
14.45-14.55	SINGLE CELL TRANSCRIPTOMICS REVEALED MOLECULAR ALTERATIONS IN AML CELL CLUSTERS RELEVANT TO REFRACTORY DISEASE AT RELAPSE Alessandra Conforte, NUIG
14.55-15.05	OUTCOME OF PATIENTS DIAGNOSED AND TREATED WITH ACUTE LYMPHOBLASTIC LEUKAEMIA IN ST JAMES HOSPITAL: A SINGLE INSTITUTION STUDY Bryan Dillon, St. James's Hospital
15.05-15.15	METABOLIC CHANGES IN VENETOCLAX RESISTANCE ARE DETERMINED BY DIFFERENTIATION STATE IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Andrew Roe, RCSI
15.15-16.00	STATE OF THE ART LECTURE – Introduced by: Prof. Feargal McNicholl <i>"A Vancouver to Belfast Experience"</i> <i>Dr Nicholas Cunningham, MB BAO BCh BSc(Hons) MRP FRCPath</i> Consultant Haematologist with a specialist interest in leukaemia and stem cell transplantation, Belfast City Hospital
16.00	Day 1 Closing Comments Professor James O'Donnell, President

This meeting is kindly sponsored by: AbbVie, Accord Healthcare, Amgen, Astellas, Bristol-Myers Squibb, Gilead, Incyte, Janssen, Jazz Pharma, Leo Pharma, Mallinckrodt Pharmaceuticals, Novartis, ONCOassist, Pfizer Hospital, Pfizer Oncology, Roche and Takeda
(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)



ANNUAL MEETING PROGRAMME

Friday 1st October 2021

09.30-10.00	POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>
10.00-10.05	Opening of Day 2 - Annual HAI Meeting – Prof. James O'Donnell, President
10.05	SESSION 3 – Oral Presentations 7 x 10 minute Presentations Chairpersons: Dr Andrea Malone and Dr Barry Kevane
10.05-10.15	COAGULATION-CANCER CROSSTALK; VON WILLEBRAND FACTOR CONTRIBUTES TO PRO- INVASIVE AND PRO-ANGIOGENIC PROPERTIES IN BREAST CANCER CELLS Sean Patmore, RCSI
10.15-10.25	A ROLE FOR MUC1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA Aidan Kelly, Trinity St. James' Cancer Institute
10.25-10.35	METABOLIC REPROGRAMMING IS ESSENTIAL FOR MYELOID CELL PROCOAGULANT AND ANTIFIBRINOLYTIC ACTIVITY Aisling Rehill, RCSI
10.35-10.45	GENERATION OF NATURAL KILLER CELL MIMIC NANOPARTICLES TO TARGET TUMOUR CELLS Hojjat Alizadeh Zeinabad, NUIG
10.45-10.55	USE OF THERAPEUTIC PLASMA EXCHANGE (TPE) TO TREAT ACUTE MULTIPLE SCLEROSIS (MS) RELAPSE IN PREGNANCY Lorraine Lester, IBTS
10.55-11.05	FRAILTY IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION: DEVELOPING TOOLS TO IDENTIFY VULNERABILITY AND IMPROVE SURVIVORSHIP Kate Banks, St James's Hospital
11.05-11.15	ACTIVATED PROTEIN C REGULATES COLITOGENIC T CELL ACTIVITY Gemma Leon, RCSI
11.15-11.30	Novartis Fellowship Update – 2019 Winner Dr Luke Jones, Systems Biology Ireland, UCD
11.30-12.15	STATE OF THE ART LECTURE – Introduced by: Dr Andrea Malone "CAR T cell therapy for paediatric ALL- where to next?" Prof. Persis Amrolia Professor of Transplantation Immunology UCL Great Ormond St Institute of Child Health and Director of BMT Great Ormond St Children's Hospital
12.15-13.00	POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>
13.00-14.00	PRESIDENT'S SYMPOSIUM – Chairpersons: Professor James O'Donnell and Professor Feargal McNicholl
13.00-13.15	HUWE1 orchestrates DNA Repair in response to Replicative Stress in Multiple Myeloma Jonathan Morgan, QUB
13.15-13.30	PERSISTENT ENDOTHELIOPATHY IN THE PATHOGENESIS OF LONG COVID SYNDROME Helen Fogarty, RCSI
13.30-13.45	TC BUSTER TRANSPOSON ENGINEERED CLL-1 CAR-NK CELLS EFFICIENTLY TARGET ACUTE MYELOID LEUKAEMIA Mark Gurney, NUIG
13.45-14.00	CAR T CELL THERAPY FOR HIGH GRADE B CELL LYMPHOMA, IRISH PATIENTS AVAILING OF THERAPY IN KING COLLEGE HOSPITAL AND UNIVERSITY COLLEGE HOSPITAL, LONDON Feargal McGlynn, St James's Hospital



ANNUAL MEETING PROGRAMME

Friday 1st October 2021

14.00-15.00	LIAM O'CONNELL LECTURE - Introduced by: Dr Jamie O'Sullivan <i>Professor Christophe Dubois</i> <i>Professor of Cell Biology, Aix Marseille University, Marseille</i>
15.00	CLOSE OF CONFERENCE AND AWARDING OF EDUCATIONAL AWARDS

This meeting is kindly sponsored by: AbbVie, Accord Healthcare, Amgen, Astellas, Bristol-Myers Squibb, Gilead, Incyte, Janssen, Jazz Pharma, Leo Pharma, Mallinckrodt Pharmaceuticals, Novartis, ONCOassist, Pfizer Hospital, Pfizer Oncology, Roche and Takeda
(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)